RA CAPITAL MANAGEMENT, L.P., DIR, reported an open-market or private purchase at Janux Therapeutics, Inc. involving 372093.000000 shares for an estimated $11453022.54. Reported holdings after the transaction were 10031081.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
No officer title
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.90 to $30.89 inclusive. The Reporting Persons undertake to p…
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management…
Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.90 to $31.50 inclusive. The Reporting Persons undertake to p…
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 to $31.00 inclusive. The Reporting Persons undertake to p…
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.74 to $31.40 inclusive. The Reporting Persons undertake to p…
Held directly by the Nexus Fund II.
0 other filings
0 recent txs